Platelet-rich plasma: support for its use in wound healing.
Previous topical growth factor studies have shown that recombinant human platelet-derived growth factor-BB isomer (rhPDGF-BB) is an efficacious treatment of chronic diabetic foot ulceration. A newer treatment, autologous platelet-rich plasma (PRP), represents a greater similarity to the natural healing process as a composite of multiple growth factors, is safe due to its autologous nature, and is produced as needed from patient blood. A review of the literature shows few studies performed with scientific rigor, although the safety of PRP appears to be validated. As the use of PRP increases, additional studies may establish PRP as an efficacious treatment modality and guide future treatment of chronic diabetic foot ulceration.
Lacci
Kathleen M
KM
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520-8089, USA.
Dardik
Alan
A
D000077214:Becaplermin; D001804:Blood Transfusion, Autologous; D002986:Clinical Trials as Topic; D017719:Diabetic Foot / Q000188:drug therapy; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D053657:Platelet-Rich Plasma / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis; D014945:Wound Healing
D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin